| HOME >> BIOLOGY >> TECHNOLOGY |
6,2382,515Loss from operations
(6,238)(2,515)Other income (expense), net
(330)(352)Net loss and comprehensive loss
(6,568)(2,867)Accretion of redeemable convertible preferred shares
-941Net loss attributable to common shareholders
$ (6,568)$ (3,808)Basic and diluted loss per share
$ 0.26)$ (7.13)Basic and diluted weighted average shares outstanding
24,904534Full Year Ended December 31,20122011Revenues
$
-$
-Operating expenses
Research and development
16,86916,872
General and administrative
6,0683,708
Total costs and expenses
22,93720,580Loss from operations
(22,937)(20,580)Other income (expense), net
(1,289)(641)Net loss and comprehensive loss
(24,226)(21,221)Accretion of redeemable convertible preferred shares
(314)(3,763)Net loss attributable to common shareholders
$
(24,540)$
(24,984)Basic and diluted loss per share
$
(1.23)$
(47.53)Basic and diluted weighted average shares outstanding
19,883525.7
Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.co
'/>"/>
| SOURCE Cempra, Inc. Copyright©2012 PR Newswire. All rights reserved |